MET fusions are targetable genomic variants in the treatment of advanced malignancies

Dantong Sun,Xiaoming Xing,Yongjie Wang,Helei Hou

DOI: https://doi.org/10.1186/s12964-023-01454-0

IF: 7.525

2024-01-11

Cell Communication and Signaling

Abstract:Targeted therapy for malignancies has developed rapidly in recent years, benefiting patients harboring genetic mutations sensitive to relevant tyrosine kinase inhibitors (TKIs). With the development of targeted sequencing techniques, an increasing number of detectable genomic alterations in malignancies, including MET fusions, have been revealed. MET fusions, although rare among malignancies, might be functional driver genes that participate in activating downstream signaling pathways and promoting cell proliferation. Therefore, it is believed that MET fusions could be targetable genomic variants of MET , and inhibition of MET is considered an optionable therapeutic choice for patients harboring MET fusions. According to the summary presented in this review, we recommend MET-TKIs as suitable treatment agents for patients harboring primary MET fusions. For patients harboring acquired MET fusions after the development of resistance to TKIs targeting primary genomic alterations, such as sensitive EGFR mutations, treatment with a MET-TKI alone or in combination with TKIs targeting primary genomic alterations, such as EGFR-TKIs, is hypothesized to be a reasonable option for salvage treatment. In summary, MET fusions, despite their low incidence, should be taken into consideration when developing treatment strategies for cancer patients.

cell biology

What problem does this paper attempt to address?

The paper aims to explore the role and significance of MET gene fusion in the treatment of malignant tumors. Specifically, the researchers focused on MET gene fusion as a targetable genetic variation and its potential in treating advanced malignant tumors. Although MET gene fusion is relatively rare in malignant tumors, it may act as a functional driver gene involved in activating downstream signaling pathways and promoting cell proliferation. Therefore, inhibiting MET is considered a potential therapeutic option for patients with MET gene fusion. The paper addresses the following key issues: 1. **Incidence of MET gene fusion**: By using online databases and published studies, the incidence of MET gene fusion in different cancer types was determined, and the demographic characteristics of the affected patients were analyzed. 2. **Oncogenic function of MET gene fusion at the cellular level**: Based on previous studies, the oncogenic mechanisms of MET gene fusion at the cellular level were summarized. 3. **Treatment options for patients with MET gene fusion**: The treatment cases of patients with MET gene fusion, particularly the efficacy of MET tyrosine kinase inhibitors (MET-TKIs), were summarized. The study showed that various MET-TKIs are effective for patients with MET gene fusion, especially Crizotinib, which demonstrated significant efficacy in multiple cases. In conclusion, although the incidence of MET gene fusion is low, it should still be considered when formulating treatment strategies for cancer patients.

MET fusions are targetable genomic variants in the treatment of advanced malignancies

Potential Therapeutics Specific to C-Met/ron Receptor Tyrosine Kinases for Molecular Targeting in Cancer Therapy.

Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer

Progress and Challenge in Development of Biotherapeutics Targeting MET Receptor for Treatment of Advanced Cancer.

Targeting MET in Non-Small Cell Lung Cancer: an Ever-Expanding Territory

Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase

Mutations in the MET Tyrosine Kinase Domain and Resistance to Tyrosine Kinase Inhibitors in Non-Small-cell Lung Cancer

Targeting MET in NSCLC: An Ever-Expanding Territory

MET alterations and therapeutic strategies in non-small cell lung cancer

Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer

Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer

Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study

MET alterations in advanced non-small cell lung cancer

Genomic Characterization and Outcome Evaluation of Kinome Fusions in a Large Non-Small Cell Lung Cancer Population.

Cmet As A Potential Therapeutic Target In Gastric Cancer

Comprehensive analysis of <i>MET</i> mutations in NSCLC patients in a real-world setting

MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature

Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors

Recording and classifying MET receptor mutations in cancers

Landscape of Potentially Targetable Receptor Tyrosine Kinase Fusions in Diverse Cancers by DNA-based Profiling